(RTTNews) - Galectin Therapeutics, Inc. (GALT), on Tuesday, announced additional data from the NAVIGATE trial showing a significant 68.1% reduction in the incidence of new varices in U.S. patients treated with belapectin.
Belapectin, a galectin-3 inhibitor, is being developed for the treatment of Metabolic Dysfunction-Associated SteatoHepatitis or MASH cirrhosis and portal hypertension.
In the U.S. cohort of the trial, the incidence of new varices was significantly lower in the belapectin group compared to placebo, showing promising potential for the drug in treating patients with this chronic liver condition.
These results provide further evidence of belapectin's potential in preventing disease progression in MASH cirrhosis, where currently no FDA-approved therapies exist.
Galectin plans to continue analyzing the data, including results from patients who completed 36 months of treatment, with additional updates expected in the first quarter of 2025.
Joel Lewis, CEO of Galectin Therapeutics, stated, "The 68% reduction in new varices from the NAVIGATE trial highlights belapectin's potential as an important treatment for MASH cirrhosis and portal hypertension, underscoring the need for new therapies to address this pressing medical issue."
Currently, GALT is trading at $1.47 up by 4.25%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
